Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus brevis CD2 for Oral Mucositis in HSCT
NCT02085694Phase 3Unknown
- Sponsor
- Università Cattolica del Sacro Cuore
- Start
- Mar 2014
- Primary completion
- Nov 2014
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lactobacillus brevis cd2 in oral mucositis (OM), sponsored by Università Cattolica del Sacro Cuore. Primary endpoint: Common Terminology Criteria for Adverse Events (CTCAE) v4.03 for evaluation of change in oral mucositis. Status: unknown.
02
Drugs
lactobacillus brevis cd2
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT02085694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085694.